Zofková I
Endokrinologický ústav, Praha.
Cas Lek Cesk. 2007;146(3):246-50.
Fundamental cytokine regulating remodelation of the skeleton is receptor activator of nuclear factor kappa B ligand (RANKL). RANKL is counter regulated by soluble receptor osteoprotegerin (OPG). While RANKL activates osteoclastic bone resorption, the OPG stimulates bone formation. RANKL/OPG system (TRANCE axis) is activated in favour of RANKL in estrogen deficiency, inflammation, bone malignancies and during the treatment with glucocorticoids. TRANCE axis is functional also in other tissues including vessel wall, where dysbalance with superiority of RANKL leads to atherogenesis. Molecules blocking RANKL (specific antibodies and OPG) are potential drugs for treatment of osteoporosis, atherosclerosis, inflammation diseases, myeloma or osteolytic bone metastases. This review is focused on pathogenetic role of TRANCE axis in the development of osteoporosis and atherosclerosis and on its use in diagnosis and treatment of both degenerative diseases.
调节骨骼重塑的关键细胞因子是核因子κB受体活化因子配体（RANKL）。RANKL受到可溶性受体骨保护素（OPG）的反向调节。RANKL激活破骨细胞的骨吸收，而OPG则刺激骨形成。在雌激素缺乏、炎症、骨恶性肿瘤以及糖皮质激素治疗期间，RANKL/OPG系统（TRANCE轴）被激活，有利于RANKL。TRANCE轴在包括血管壁在内的其他组织中也有功能，在这些组织中，RANKL优势导致的失衡会引发动脉粥样硬化。阻断RANKL的分子（特异性抗体和OPG）是治疗骨质疏松症、动脉粥样硬化、炎症性疾病、骨髓瘤或溶骨性骨转移的潜在药物。本综述重点关注TRANCE轴在骨质疏松症和动脉粥样硬化发生发展中的致病作用及其在这两种退行性疾病诊断和治疗中的应用。
